Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
50,606,433
-
Shares change
-
+1,081,182
-
Total reported value, excl. options
-
$1,234,538,861
-
Value change
-
+$33,125,299
-
Put/Call ratio
-
19.7%
-
Number of buys
-
90
-
Number of sells
-
-44
-
Price
-
$24.42
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2020
156 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50,606,433 shares
of 104,661,494 outstanding shares and own 48.35% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4,439,200 shares), JPMORGAN CHASE & CO (4,027,774 shares), WELLINGTON MANAGEMENT GROUP LLP (3,756,798 shares), ArrowMark Colorado Holdings LLC (3,579,711 shares), FRANKLIN RESOURCES INC (3,466,888 shares), Essex Woodlands Management, Inc. (3,342,047 shares), VANGUARD GROUP INC (2,894,383 shares), ALLIANCEBERNSTEIN L.P. (2,792,810 shares), Capital World Investors (2,130,000 shares), and JENNISON ASSOCIATES LLC (2,126,541 shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.